Open Access<p>Clinical Characteristics and Prognosis of Gastric Cancer Patients with <em>BRCA 1/2</em> Germline Mutations: Report of Ten Cases and a Literature Review</p>
Author(s) -
Naama Halpern,
Albert Grinshpun,
Ben Boursi,
Talia Golan,
Ofer Margalit,
Dan Aderka,
Eitan Friedman,
Yael Laitman,
Ayala Hubert,
Luna Kadouri,
Tamar Hamburger,
Inbal Barnes-Kedar,
Zohar Levi,
Irit BenAharon,
Baruch Brenner,
Yael Goldberg,
Tamar Peretz,
Einat ShachamShmueli
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s276814
Subject(s) - medicine , oncology , disease , cancer , stage (stratigraphy) , biomarker , germline , ovarian cancer , gastroenterology , breast cancer , overall survival , gene , paleontology , biochemistry , chemistry , biology
The prognosis of gastric cancer (GC) is poor with a median overall survival (OS) of less than 12 months in advanced-stage disease. The search for distinct genetic subgroups of GC patients and predictive biomarkers is ongoing. While BRCA1 or BRCA2 germline mutations (gBRCAm) have potential therapeutic implications in ovarian, breast and pancreatic cancers, their significance in GC patients has not been established.